EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Risk of Major Congenital Malformations Associated With the First‐Trimester Exposure to Antipsychotics: A Large Claims Database Study

Ryo Obara, Takamasa Sakai iD, Tomofumi Ishikawa, Kei Morishita, Motohiko Adomi iD, Azusa Hara, Saya Kikuchi iD, Natsuko Kobayashi, Noriyuki Iwama iD, Genki Shinoda, Aoi Noda iD, Masatsugu Orui iD und 5 weitere

Pharmacology Research & Perspectives · 2026-04 · 14 (2)

DOI: 10.1002/prp2.70231 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmacology Research & Perspectives, online erschienen am 11.03.2026. Verfasst von Ryo Obara und 16 weiteren Autor:innen. Beteiligte Einrichtung: Division of Molecular Epidemiology, Graduate School of Medicine, Tohoku University, Sendai, Miyagi, Japan. Hauptthemen laut MEDLINE: Antipsychotic Agents, Abnormalities, Drug-Induced, Pregnancy Complications, Mental Disorders. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 69 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The Ministry of Health, Labour and Welfare of Japan, The Research Institute of Healthcare Data Science., The Japan Society for the Promotion of Science.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This study aimed to evaluate the risk of major congenital malformations (MCMs) associated with first‐trimester exposure to antipsychotics, using a large claims database in Japan. This retrospective cohort study was based on data from a large claims database in Japan. We used a large claims database from 2010 to 2019. Dates of pregnancy onset and delivery were estimated using the developed algorithms. Overall MCMs were defined according to the International Classification of Diseases, 10th revision codes. To address confounding by indication, the risk of MCM in relation to first‐trimester antipsychotic use was evaluated among pregnant women with psychiatric disorders diagnosed before the end of the first‐trimester. We compared the prevalence of MCMs among infants born to pregnant women with or without first‐trimester exposure to antipsychotics and estimated the weighted odds ratios (wORs) using propensity‐score overlap weights. The prevalence of psychiatric diagnoses before the end of the first‐trimester was 6291 women among the 91 390 who delivered between 2010 and 2019. Among the 6291 diagnosed with psychiatric disorders, 317 were exposed to any antipsychotics during the first‐trimester of pregnancy. The prevalence of overall MCMs among live births was 411 (6.9%) among women unexposed to any antipsychotics and 24 (7.6%) among those exposed. The first‐trimester exposure to any antipsychotics was not significantly associated with overall MCMs when wORs were calculated using propensity‐score overlap weights (wOR 1.144, 95% confidence intervals 0.727–1.799). Exposure to any antipsychotics during the first‐trimester of pregnancy was not associated with an increased risk of overall MCMs in infants.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antipsychotic AgentsAbnormalities, Drug-InducedPregnancy ComplicationsMental DisordersHumansFemalePregnancyPregnancy Trimester, FirstJapanRetrospective StudiesDatabases, FactualAdultInfant, NewbornPrevalence

Stichwörter der Autor:innen

antipsychoticsclaims databasecongenital malformationsfirst‐trimester exposurepharmacoepidemiologypregnancy

Substanzen

Antipsychotic Agents

Autor:innen und Institutionen

  • Division of Molecular Epidemiology, Graduate School of Medicine, Tohoku University, Sendai, Miyagi, Japan.
  • Drug Informatics, Faculty of Pharmacy, Meijo University, Nagoya, Aichi, Japan.
  • Laboratory of Biomolecule and Pathophysiological Chemistry, Graduate School of Pharmaceutical Sciences, Tohoku University, Sendai, Miyagi, Japan.
  • Department of Pharmaceutical Sciences, Tohoku University Hospital, Sendai, Miyagi, Japan.
  • Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.
  • Laboratory of Social Pharmacy and Epidemiology, Showa Pharmaceutical University, Machida, Tokyo, Japan.

ORCID-Profile: Takamasa Sakai, Motohiko Adomi, Saya Kikuchi, Noriyuki Iwama, Aoi Noda, Masatsugu Orui, Taku Obara

Förderung

  • The Ministry of Health, Labour and Welfare of Japan
  • The Research Institute of Healthcare Data Science.
  • The Japan Society for the Promotion of Science
  • Ministry of Health, Labour and Welfare

Zitieren

APA

Obara, R., Sakai, T., Ishikawa, T., Morishita, K., Adomi, M., Hara, A., Kikuchi, S., Kobayashi, N., Iwama, N., Shinoda, G., Noda, A., Orui, M., Ishikuro, M., Tomita, H., Mano, N., Kuriyama, S., & Obara, T. (2026). Risk of Major Congenital Malformations Associated With the First‐Trimester Exposure to Antipsychotics: A Large Claims Database Study. Pharmacology Research & Perspectives, 14(2). https://doi.org/10.1002/prp2.70231

Vancouver

Obara R, Sakai T, Ishikawa T, Morishita K, Adomi M, Hara A, et al. Risk of Major Congenital Malformations Associated With the First‐Trimester Exposure to Antipsychotics: A Large Claims Database Study. Pharmacology Research & Perspectives. 2026;14(2). doi:10.1002/prp2.70231

BibTeX
@article{Obara2026,
  author = {Obara, Ryo and Sakai, Takamasa and Ishikawa, Tomofumi and Morishita, Kei and Adomi, Motohiko and Hara, Azusa and Kikuchi, Saya and Kobayashi, Natsuko and Iwama, Noriyuki and Shinoda, Genki and Noda, Aoi and Orui, Masatsugu and Ishikuro, Mami and Tomita, Hiroaki and Mano, Nariyasu and Kuriyama, Shinichi and Obara, Taku},
  title = {Risk of Major Congenital Malformations Associated With the First‐Trimester Exposure to Antipsychotics: A Large Claims Database Study},
  journal = {Pharmacology Research & Perspectives},
  year = {2026},
  volume = {14},
  number = {2},
  doi = {10.1002/prp2.70231}
}
Kostenlos starten →